KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Tax Provisions (2024 - 2025)

Biocryst Pharmaceuticals' Tax Provisions history spans 2 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 170.15% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $3.5 million, up 83.19%, while the annual FY2025 figure was $3.5 million, 83.19% up from the prior year.
  • Tax Provisions reached $2.2 million in Q4 2025 per BCRX's latest filing, up from -$769000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.2 million in Q4 2025 to a low of -$769000.0 in Q3 2025.